October 19, 2020 -- Anti-infective therapies firm Aridis Pharmaceutical has developed an inhalable highly neutralizing monoclonal antibody (mAb) that eradicated the novel coronavirus in infected rodents.
October 19, 2020 -- Cell therapeutics company Akron Biotechnology and respirator drug development firm Synairgen have partnered to advance interferon-beta (IFN-beta) treatment for patients with COVID-19.
October 19, 2020 -- Ultimovacs reported five-year overall survival data from its phase I clinical trial evaluating UV1, a universal cancer vaccine candidate, in patients with non-small cell lung cancer.
October 19, 2020 -- Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.
October 19, 2020 -- Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their candidates. The service will combine Reaction's ProLiFiler cell assay service with 4HF's Biomarker Analysis and Mode of Action (MoA) Finder tools
October 19, 2020 -- OneOncology has formed a subsidiary named OneOncology Research Network (OneR) as a national nonexclusive clinical trial site management organization to enhance research programs underway at participating community oncology practices.
October 19, 2020 -- Oncopeptides has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for OPD5, a second drug candidate based on its proprietary peptide drug conjugate platform.
October 19, 2020 -- Endo will acquire all shares of BioSpecifics Technologies for $88.50 per share, or an estimated total of $540 million. As part of the acquisition, BioSpecifics will receive a royalty stream from Endo's collagenase-based therapies, including Xiaflex and Qwo, which were developed by BioSpecifics.
October 16, 2020 -- The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Bristol Myers Squibb's nivolumab (Opdivo).
October 16, 2020 -- The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval for the expanded use of guselkumab (Tremfya), a monoclonal antibody (mAb) from the Janssen Pharmaceutical Companies of Johnson & Johnson.
Conferences
Cell and Gene Therapy Bioprocessing and Commercialization
October 19-22
Online
October 19-22
Online
New Applications of Synthetic Biology to Cancer Research Challenges: 2020 Virtual Jumpstart
October 26-30
Online
October 26-30
Online
Japan Analytical & Scientific Instruments Show (JASIS)
November 11-13
Chiba, Chiba Japan
November 11-13
Chiba, Chiba Japan
2020 AACC Annual Scientific Meeting & Clinical Lab Expo
December 13-17
Online
December 13-17
Online
Society for Laboratory Automation and Screening (SLAS) 2021
January 23-27, 2021
San Diego, California United States
January 23-27, 2021
San Diego, California United States
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
